This present disclosure relates to compounds with ferroptosis inducing activity, a method of treating a subject with cancer with the compounds, and combination treatments with a second therapeutic agent.

A process for producing an organic compound using a flow reactor for a first reaction in which a raw material liquid A and a raw material liquid B are mixed, and reacted in a reactor unit, and a flow reactor for a second reaction in which a first reaction solution discharged from the flow reactor for the first reaction and a raw material liquid C are mixed, and reacted in a reactor unit, wherein the raw material liquid A is a solution in which triphosgene and/or diphosgene is dissolved, wherein the raw material liquid B is a nitrogen-containing organic compound or a solution thereof, wherein the raw material liquid C is a reaction substrate having a functional group capable of reacting with phosgene, or a solution containing the reaction substrate, and wherein a product of the first reaction is phosgene.

A process for producing an organic compound using a flow reactor for a first reaction in which a raw material liquid A and a raw material liquid B are mixed, and reacted in a reactor unit, and a flow reactor for a second reaction in which a first reaction solution discharged from the flow reactor for the first reaction and a raw material liquid C are mixed, and reacted in a reactor unit, wherein the raw material liquid A is a solution in which triphosgene and/or diphosgene is dissolved, wherein the raw material liquid B is a nitrogen-containing organic compound or a solution thereof, wherein the raw material liquid C is a reaction substrate having a functional group capable of reacting with phosgene, or a solution containing the reaction substrate, and wherein a product of the first reaction is phosgene.

In some aspects, the present disclosure provides compounds of the formula: (I) or (II) wherein the variables are as defined herein. In some embodiments, these compounds may be used to treat cancer or other hyperproliferative diseases, as well as atherosclerosis and coronary artery disease.

In some aspects, the present disclosure provides compounds of the formula: (I) or (II) wherein the variables are as defined herein. In some embodiments, these compounds may be used to treat cancer or other hyperproliferative diseases, as well as atherosclerosis and coronary artery disease.

Provided herein are compounds, derivatives thereof, composition comprising one or more of said compounds and derivatives, and methods for prevention and/or treatment of microbial infections and/or related diseases or conditions. The present compounds and/or derivatives thereof can be represented by Formula (II):

##STR00001##

The present methods include administering to a subject an effective amount of one or more compounds of Formula (II). In one embodiment, said microbial infections are bacterial infections. More specifically, said bacterial infections are staphylococcal infections.

Provided herein are compounds, derivatives thereof, composition comprising one or more of said compounds and derivatives, and methods for prevention and/or treatment of microbial infections and/or related diseases or conditions. The present compounds and/or derivatives thereof can be represented by Formula (II):

##STR00001##

The present methods include administering to a subject an effective amount of one or more compounds of Formula (II). In one embodiment, said microbial infections are bacterial infections. More specifically, said bacterial infections are staphylococcal infections.

The present invention provides a novel compound that increases KAI1 promoter activity, a pharmaceutically acceptable salt thereof, and a composition for inhibiting cancer metastasis and invasion or treating colorectal cancer containing the same.

The present invention provides a novel compound that increases KAI1 promoter activity, a pharmaceutically acceptable salt thereof, and a composition for inhibiting cancer metastasis and invasion or treating colorectal cancer containing the same.

The present disclosure relates to compounds that are capable of inhibiting the ENPP1 gene and treating a variety of cardiac conditions. The disclosure further relates to methods of treating or preventing cardiac conditions, such as myocardial infarction and heart failure.